QT VASCULAR LTD.
(Company Registration No. 201305911K)
(Incorporated in Singapore)

POTENTIAL LEGAL PROCEEDINGS WITH INNORA GMBH

Unless otherwise defined herein, all capitalised terms used in this announcement shall have the same meaning ascribed to them in the Company's previous announcement dated 27 August 2020 which highlighted the InnoRa Dispute.

The Board of Directors ("**Directors**") of QT Vascular Ltd. ("**Company**", and together with its subsidiaries, "**Group**") wishes to announce that on 27 August 2021, InnoRa GmbH ("**InnoRa**"), a licensor to TriReme Medical LLC ("**TriReme**", a subsidiary of the Company in which the Company owns 1 share more than 50% of TriReme), of intellectual property for the application and incorporation of certain coating technologies with and into balloon catheters under a development and licence agreement dated 3 April 2011 between InnoRa and TriReme pertaining to Chocolate Touch® ("**Product**"), is seeking to claim an amount of USD1,200,000 in royalties, being 30% of the initial payment made to TriReme, under the Sublicense Agreement of the asset purchase agreement between the Company, TriReme, G Vascular Private Limited ("**Purchaser**") and Genesis MedTech International Private Limited in relation to the disposal of the Product by TriReme to the Purchaser as announced in the Company's announcement dated 27 August 2020, to be paid not later than 10 September 2021 as well as 30% of all future payments received by TriReme in connection with the aforesaid disposal.

The Company disputes the claim by InnoRa and has engaged Arnold & Porter Kaye Scholer LLP, as legal counsel in the United States, to defend its interest.

For the avoidance of doubt, InnoRa has not commenced any formal legal proceedings against TriReme as at the date of this announcement, although it has threatened to do so, if its claims are not satisfied.

The Company will make the necessary announcements in compliance with the Catalist Rules and as and when there are further material developments.

By Order of the Board of Directors
QT VASCULAR LTD.

Eitan Konstantino
Chief Executive Officer
30 August 2021

---

*This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. ("**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

The contact person for the Sponsor is Ms Lim Hui Ling, 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, sponsorship@ppcf.com.sg.